MedTrace Logo

Therapy With New Oral Anticoagulants

NCT02222090 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2014-08-21

No results posted yet for this study

Summary

The aim of the present registry is to characterize and follow patients prospectively and retrospectively with renal impairment who have been prescribed apixaban for the prevention of stroke in atrial fibrillation, with a comparison to the characteristics and outcomes associated with warfarin therapy in this population.

Conditions

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Ilan Goldenberg, Prof · Sheba Medical Center

  • Alon Barsheshet, MD · beilinson Medical Center

  • Avishay Elias, MD · beilinson Medical Center

  • Shmuel Fuchs, Prof · beilinson Medical center

  • KIRILL BUTURLIN, MD · Meir Medical Center

  • Moshe Swissa, MD · Kaplan Medical Center

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2016-07-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02222090 on ClinicalTrials.gov